Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan L Crass

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Pharmacology|August 12, 2025
Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea ManagementHoa Q Nguyen, Ryan L Crass, Sunny Chapel, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2021
Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic FibrosisRyan L Crass, Tamara Al Naimi, Bo Wen, et al.
Ophthalmology Science|January 24, 2025
Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular DegenerationRyan L Crass, Komal Prem, Francois Gauderault, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 27, 2023
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemiaSatyawan B Jadhav, Benny M Amore, Howard Bockbrader, et al.
Clinical Pharmacokinetics|December 11, 2021
Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19Elizabeth Leung, Ryan L Crass, Sarah C J Jorgensen, et al.
Journal of Clinical Pharmacology|July 25, 2024
A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive DyskinesiaHoa Q Nguyen, Han-Yi Steve Kuan, Ryan L Crass, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycinMadeline A Lipp, Ryan L Crass, Linda J Fitzgerald, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2018
Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body SizeRyan L Crass, Brian E Ross, Brian A Derstine, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 27, 2021
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response modelSatyawan B Jadhav, Ryan L Crass, Sunny Chapel, et al.
The Lancet. Infectious Diseases|May 18, 2025
The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustmentsAnne-Grete Märtson, Katie E Barber, Ryan L Crass, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Clinical Pharmacology|August 12, 2025
Population Pharmacokinetic and Exposure-Efficacy Analyses of Valbenazine in Patients with Huntington's Disease: Supporting Dose Selection for Chorea ManagementHoa Q Nguyen, Ryan L Crass, Sunny Chapel, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2021
Pharmacokinetics of Polymyxin B in Hospitalized Adults with Cystic FibrosisRyan L Crass, Tamara Al Naimi, Bo Wen, et al.
Ophthalmology Science|January 24, 2025
Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular DegenerationRyan L Crass, Komal Prem, Francois Gauderault, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 27, 2023
Population pharmacokinetic and pharmacokinetic-pharmacodynamic modeling of bempedoic acid and low-density lipoprotein cholesterol in healthy subjects and patients with dyslipidemiaSatyawan B Jadhav, Benny M Amore, Howard Bockbrader, et al.
Clinical Pharmacokinetics|December 11, 2021
Pharmacokinetic/Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19Elizabeth Leung, Ryan L Crass, Sarah C J Jorgensen, et al.
Journal of Clinical Pharmacology|July 25, 2024
A Model-Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive DyskinesiaHoa Q Nguyen, Han-Yi Steve Kuan, Ryan L Crass, et al.
The Journal of Antimicrobial Chemotherapy|June 9, 2022
Acute kidney injury in cystic fibrosis patients treated with intravenous colistimethate sodium or tobramycinMadeline A Lipp, Ryan L Crass, Linda J Fitzgerald, et al.
Antimicrobial Agents and Chemotherapy|April 11, 2018
Measurement of Skeletal Muscle Area Improves Estimation of Aminoglycoside Clearance across Body SizeRyan L Crass, Brian E Ross, Brian A Derstine, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|August 27, 2021
Pharmacodynamic effect of bempedoic acid and statin combinations: predictions from a dose-response modelSatyawan B Jadhav, Ryan L Crass, Sunny Chapel, et al.
The Lancet. Infectious Diseases|May 18, 2025
The pharmacokinetics of antibiotics in patients with obesity: a systematic review and consensus guidelines for dose adjustmentsAnne-Grete Märtson, Katie E Barber, Ryan L Crass, et al.
Pageof 3